NVIDIA Corporation (NASDAQ:NVDA) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 1.76% to $91.17. The highly anticipated NVIDIA (NVDA) GeForce GTX 1080 Ti is rumored to be launched at the CES event in January 2017. The new model is rumored to be superior than the GTX Titan X and been the subject of all the tech hype lately. Will it live up to the expectations?The Consumer Electronic Show is for the tech enthusiasts as well as the gamers. It is a place where people from the tech industry gather to discuss consumer technologies and the businesses revolving around it. The CES is where NVIDIA is going to launch its new GTX 1080 Ti.
GTX 1080 Ti Review; The GTX 1080 Ti brings better performance to the table with its GP102 GPU, 208 texture mappings features, 3328 CUDA cores, and its 160 render output units, Neuro Gadget declared. Meanwhile, the GTX Titan X only has 28nm GM200-400 GPU, 192 texture mapping units, 3072 CUDA cores, and 96 render output units. The GTX 1080 Ti also has an impressive graphics card with a 1503MHz clock speed and 10 teraflops HP. While the GTX Titan X only has a video card with a clock speed of 1002MHz. The share price of NVDA attracts active investors, as stock price of week volatility recorded 3.30%. The stock is going forward to its 52-week low with 271.90% and lagging behind from its 52-week high price with -5.64%.
Moleculin Biotech, Inc. (NASDAQ:MBRX) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -3.17% to close at $1.80 with the total traded volume of 178568 shares. Moleculin Biotech, (NASDAQ:MBRX) declared that its scientific presentation at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. Waldemar Priebe, PhD, Moleculin’s Founder, Founding Scientist, and Chair of the Scientific Advisory Board presented the Abstract on November 30th at the Symposium in Munich, Germany.
Wally Klemp, Chairman and CEO stated, “This presentation shows proof of concept data for our WP1122 portfolio, including data demonstrating surged survival of animals with human brain tumors treated with WP1122, as well as its biodistribution and pharmacokinetics. In non-optimal doses and treatment regimens, our lead inhibitor WP1122 performed equal to or better than the current market leader, cytotoxic drug temozolomide and importantly improved survival in animals treated with WP1122 in combination with temozolomide.”